FIELD: pharmaceuticals.
SUBSTANCE: invention relates to a novel combined drug for use as a solid oral dosage form containing, as one of the three active components, sodium elsulfavirin. Combined drug comprises a therapeutically effective amount of sodium eslsulfavirin of 1a formula or a pharmaceutically acceptable salt thereof, and as the other two active components, a therapeutically effective amount of the nucleoside reverse transcriptase inhibitor (NRTI) of 2a–2j formulas or a pharmaceutically acceptable salt thereof and a therapeutically effective amount of a nucleotide reverse transcriptase inhibitor (NtRTI) of formula 3 or 4f, 4h, 4k, 4m or a pharmaceutically acceptable salt thereof in combination with excipients. Structural formulas of sodium elsulfavirin of 1a formula, the nucleoside reverse transcriptase inhibitor (NRTI) of formulas 2a–2j and a nucleotide reverse transcriptase inhibitor (NtRTI) of formula 3 or 4f, 4h, 4k, 4m are specified in the claims.
EFFECT: drug can be used in the treatment of viral infections, including HIV and hepatitis B (HBV) infections.
20 cl, 4 tbl, 5 ex
| Title | Year | Author | Number |
|---|---|---|---|
| HEPATITIS B (HBV) INHIBITOR | 2017 |
|
RU2666727C1 |
| CYCLOBUTYL (S)-2-[[[R)-2-(6-AMINOPURIN-9-YL)-1-METHYL-ETOXY]METHYL-PHENOXY-PHOSPHORYL]AMINO]-PROPANOATES, METHOD OF THEIR PRODUCTION AND APPLICATION | 2017 |
|
RU2647576C1 |
| ANELLATED 9-HYDROXY-1,8-DIOXO-1,3,4,8-TETRAHYDRO-2H-PYRIDO[1,2-A]PYRAZINE-7-CARBOXAMIDES - INTEGRASE INHIBITORS, METHODS FOR PREPARING AND USING THEREOF | 2019 |
|
RU2717101C1 |
| NUCLEOTIDES INCLUDING N-[(S)-1-CYCLOBUTOXYCARBONYL]PHOSPHORAMIDATE FRAGMENT, THEIR ANALOGS AND THEIR APPLICATION | 2017 |
|
RU2659388C1 |
| HEPATITIS VIRUS PENETRATION INHIBITOR AND PHARMACEUTICAL COMPOSITION FOR TREATMENT OF HEPATITIS | 2017 |
|
RU2662161C1 |
| HEPATITIS B VIRUS (HBV) INHIBITOR | 2019 |
|
RU2726456C1 |
| ACTIVE COMPONENT, PHARMACEUTICAL COMPOSITION AND DRUG PREPARATION FOR HIV AND AIDS THERAPY | 2019 |
|
RU2716257C1 |
| PANGENOTYPIC NS5A PROTEIN INHIBITOR OF HEPATITIS C VIRUS, A PHARMACEUTICAL COMPOSITION AND METHODS FOR PREPARING AND USING | 2019 |
|
RU2723482C1 |
| PHARMACEUTICAL NANOSUSPENSION FOR TREATMENT OF HIV INFECTION | 2017 |
|
RU2665383C1 |
| HEPATITIS B VIRUS (HBV) INHIBITOR, WHICH IS A DERIVATIVE OF N-{3-[6-(DIALKYLAMINO)PYRIDAZINE-3-YL]PHENYL}ARYL SULPHONAMIDE DERIVATIVES AND DERIVATIVES OF N-{4-[6-(DIALKYLAMINO)PYRIDAZINE-3-YL]PHENYL}ARYL SULPHONAMIDE | 2019 |
|
RU2738848C1 |
